U.S. Bishops’ Pro-Life Chairman Addresses Supreme Court Ruling on Abortion Drug

WASHINGTON – The Supreme Court of the United States temporarily blocked lower court rulings that would have suspended the U.S. Food and Drug Administration’s (FDA) loosening of health and safety standards for the abortion drug mifepristone. Bishop Michael F. Burbidge of Arlington, chairman of the U.S. Conference of Catholic Bishops’ Committee on Pro-Life Activities, issued the following statement in response:

“The interim order by the Supreme Court is a tremendous disappointment, both for the loss of innocent preborn life from chemical abortion, and for the danger that chemical abortion poses to women. It is wrong to allow the FDA’s greatly diminished health and safety standards for mifepristone to remain in place. The FDA acted unlawfully when it first approved, and later relaxed safety requirements for prescribing and dispensing the drug. It is our hope and prayer that the Court will eventually overturn the FDA’s improper actions.

“Abortion is never the answer for a difficult or unintended pregnancy, as it always ends one life and risks another. Meaningful compassion for both mothers and children is needed. We will continue to advocate for policies that put women and families first, serve women in need, and pray for the day when ending the lives of preborn children will become unthinkable.”